Stockpolly
Search
Delisting risk
BIVI · NASDAQ · Biotechnology

BioVie (BIVI)

Develops bezisterim and continuous-infusion terlipressin therapies.

$2.02
Pre-market−0.00 (−0.02%)
At close$2.02(−9.82%)
Watchlist

In millions of USD, except per-share figures

In millionsQ1 FY24Sep 2023Q2 FY24Dec 2023Q3 FY24Mar 2024Q4 FY24Jun 2024Q1 FY25Sep 2024Q2 FY25Dec 2024Q3 FY25Mar 2025Q4 FY25Jun 2025Q1 FY26Sep 2025Q2 FY26Dec 2025Q3 FY26Mar 2026Q4 FY26Jun 2026
Cost of revenue000000000000
Gross profit000000000000
1198547345656
Research & development966225113434
200300022222
Selling & marketing00000000000−4
General & administrative000000002226
Other expenses022023200000
Operating income−11−9−8−5−4−7−3−4−5−6−5−6
000000000000
Interest income000000000000
Interest expense111000000000
Other non-operating income−1−10000000000
Income before tax−11−8−8−5−4−7−3−3−5−6−5−6
Net income from continuing operations−11−8−8−5−4−7−3−3−5−6−5−6
Net income−11−8−8−5−4−7−3−3−5−6−5−6
EPS, basic−$2.92−$2.20−$20.00−$8.10−$7.00−$4.60−$1.50−$0.24−$0.98−$0.77−$0.70−$0.75
EPS, diluted−$2.92−$2.20−$20.00−$8.30−$7.00−$4.60−$1.50−$1.82−$0.98−$0.77−$0.70−$0.75
Weighted average shares, basic0001122155888
Weighted average shares, diluted0001122155888
EBITDA−10−8−7−4−4−7−3−3−5−6−5−6
Depreciation & amortization000000000000
EBIT−10−8−7−5−4−7−3−3−5−6−5−6